Ghassan Abou-Alfa, MD of Memorial Sloan-Kettering discusses the impact of regorafenib for hepatocellular carcinoma (HCC) treatment. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Impact of Regorafenib for HCC
